当前位置:首页 - 行情中心 - 和邦生物(603077) - 财务分析 - 现金流量表

和邦生物

(603077)

  

流通市值:261.42亿  总市值:261.42亿
流通股本:88.32亿   总股本:88.32亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,101,227,572.596,427,623,560.584,616,047,432.453,177,564,048.67
  收到的税费返还20,445,349.14113,708,087.0988,609,118.7866,091,235.85
  收到其他与经营活动有关的现金25,783,283.97115,259,286.0589,805,300.7259,706,667.83
  经营活动现金流入小计1,147,456,205.76,656,590,933.724,794,461,851.953,303,361,952.35
  购买商品、接受劳务支付的现金872,209,683.354,303,989,899.483,516,002,2542,583,031,345.51
  支付给职工以及为职工支付的现金170,823,845.22635,026,864485,630,532.41330,340,754.45
  支付的各项税费49,205,694.34489,486,461.8356,560,413.58172,153,568.48
  支付其他与经营活动有关的现金32,603,069.8151,851,097.29126,132,124.5872,366,744.54
  经营活动现金流出小计1,124,842,292.715,580,354,322.574,484,325,324.573,157,892,412.98
  经营活动产生的现金流量净额22,613,912.991,076,236,611.15310,136,527.38145,469,539.37
二、投资活动产生的现金流量:
  收回投资收到的现金-77,052,422.3977,052,422.3977,052,422.39
  取得投资收益收到的现金1,120,0001,853,787.831,853,787.831,120,000
  处置固定资产、无形资产和其他长期资产收回的现金净额237,694.76992,672.44942,906.36565,396.01
  收到的其他与投资活动有关的现金9,934,778.52115,464,579.2551,824,133.0140,056,743.08
  投资活动现金流入小计11,292,473.28195,363,461.91131,673,249.59118,794,561.48
  购建固定资产、无形资产和其他长期资产支付的现金253,023,190.11,258,913,532.7670,592,812.65469,833,381.35
  投资支付的现金-97,698,304.4297,066,904.9934,295,953.48
  支付其他与投资活动有关的现金1,330,000187,315,553.71147,724,970.3437,909,960.03
  投资活动现金流出小计254,353,190.11,543,927,390.83915,384,687.98542,039,294.86
  投资活动产生的现金流量净额-243,060,716.82-1,348,563,928.92-783,711,438.39-423,244,733.38
三、筹资活动产生的现金流量:
  吸收投资收到的现金-120,000120,000120,000
  其中:子公司吸收少数股东投资收到的现金-120,000120,000120,000
  取得借款收到的现金1,501,600,0003,900,876,713.763,443,576,713.762,683,676,713.76
  收到其他与筹资活动有关的现金72,885,716.1273,931,506.5774,061,458.4573,931,506.57
  筹资活动现金流入小计1,574,485,716.123,974,928,220.333,517,758,172.212,757,728,220.33
  偿还债务支付的现金1,170,516,373.723,367,733,749.292,654,844,534.452,093,307,295.78
  分配股利、利润或偿付利息支付的现金31,713,434.26135,774,305.3391,599,219.3260,858,628.42
  其中:子公司支付给少数股东的股利、利润-22,632.7422,632.74-
  支付其他与筹资活动有关的现金2,993,932.71327,996,857.27323,420,197.1322,699,727.46
  筹资活动现金流出小计1,205,223,740.693,831,504,911.893,069,863,950.872,476,865,651.66
  筹资活动产生的现金流量净额369,261,975.43143,423,308.44447,894,221.34280,862,568.67
四、汇率变动对现金及现金等价物的影响-24,821,057.89-38,462,235.45-21,786,823.99-7,911,681.59
五、现金及现金等价物净增加额123,994,113.71-167,366,244.78-47,467,513.66-4,824,306.93
  加:期初现金及现金等价物余额6,681,673,478.826,851,563,060.796,851,563,060.796,851,563,060.79
  期末现金及现金等价物余额6,805,667,592.536,684,196,816.016,804,095,547.136,846,738,753.86
补充资料:
  净利润--712,664,631.51-40,239,432.36
  资产减值准备-763,172,731.83-6,302,681.31
  固定资产和投资性房地产折旧-930,216,134.69-450,354,004.91
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-930,216,134.69-450,354,004.91
  无形资产摊销-66,863,984.74-26,828,454.4
  长期待摊费用摊销-392,452.8-196,226.4
  处置固定资产、无形资产和其他长期资产的损失-4,361,435.6--1,237,409.73
  固定资产报废损失-13,504,372.43-41,523.13
  财务费用-143,505,434.15-54,443,201.89
  投资损失-5,005,111.27--302,393.09
  递延所得税--35,615,185.21--11,319,132.38
  其中:递延所得税资产减少--23,269,744.9--13,606,312.39
    递延所得税负债增加--12,345,440.31-2,287,180.01
  存货的减少-304,245,999.79-338,040,532.42
  经营性应收项目的减少-540,438,280.37-19,921,903.48
  经营性应付项目的增加--990,581,733.63--792,939,171.59
  其他-15,913,023.62--
  现金的期末余额-6,684,196,816.01-6,846,738,753.86
  减:现金的期初余额-6,851,563,060.79-6,851,563,060.79
  现金及现金等价物的净增加额--167,366,244.78--4,824,306.93
公告日期2026-04-212026-04-212025-10-292025-08-20
审计意见(境内)标准无保留意见
TOP↑